Clinical characteristics and prognostic impact of HER2-ultralow breast cancer and tumor-infiltrating lymphocytes (TILs)
HER2-ultralow tumors represent a distinct subgroup characterized by higher hormone receptor positivity, whereas HER2-null tumors were associated with younger age, higher TIL density, and poorer survival. These findings emphasize the clinical significance of refining HER2-negative subclassification to distinguish HER2-ultralow, while acknowledging limitations of sample size and retrospective design.
Authors
- Mariko Nishikawa
- Chika Watanabe (ORCID: https://orcid.org/0000-0003-4905-3798)
- Tamami Morisaki
- Kana Ogisawa
- Koji Takada
- Shinichiro Kashiwagi (ORCID: https://orcid.org/0000-0002-0460-9599)
- Masatsune Shibutani (ORCID: https://orcid.org/0000-0002-2164-7394)
- Haruhito Kinoshita
- A. Kochi
Institutions
- Osaka City University (JP)
- Osaka City University Hospital (JP)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1186/s12885-025-15255-w
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00